http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
BeiGene to Host ASH Investor Meeting in Person and via Webcast on December 10, 2023
-
BeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023
-
BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor
-
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma
-
BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates
-
BeiGene to Present at the Jefferies London Healthcare Conference
-
BRUKINSA® Receives Positive Recommendation from NICE in U.K. for Adult Patients with Chronic Lymphocytic Leukemia
-
BeiGene Announces Late-Breaking Data at ESMO Showing Tislelizumab plus Chemotherapy Significantly Improved Overall Survival at Final Analysis in First-Line Advanced Gastric or Gastroesophageal Junctio
-
BeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-S
-
BeiGene Presentations at ESMO 2023 Demonstrate Robust Clinical Strategy for Tislelizumab as Monotherapy and in Combination with Pipeline Assets
-
BeiGene (BGNE) Receives Positive CHMP Opinion for BRUKINSA in Relapsed or Refractory Follicular Lymphoma
-
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma
-
BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®
-
BeiGene to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
-
BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results
-
BeiGene Announces Positive CHMP Opinion for Tislelizumab as a Treatment for Advanced or Metastatic ESCC
-
BeiGene Announces FDA Acceptance of sNDA for Fifth BRUKINSA® Indication
-
BeiGene (BGNE), DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors
-
BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors
-
BeiGene to Host Investor Research and Development Day in Person and via Webcast on July 18, 2023
-
BeiGene to Vigorously Defend Patent Infringement Allegations by Pharmacyclics
-
BeiGene Highlights Significant BRUKINSA® (zanubrutinib) Data at the 17th International Conference on Malignant Lymphoma
-
BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress
-
BeiGene' (BGNE) BRUKINSA Approved in Canada for the Treatment of Chronic Lymphocytic Leukemia
-
BRUKINSA® Approved in Canada for the Treatment of Chronic Lymphocytic Leukemia
-
BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio
-
BeiGene to Present at Upcoming Investor Conferences
-
The Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and
-
BeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in China
-
BeiGene Reports First Quarter 2023 Financial Results and Corporate Developments
-
BeiGene to Highlight Broad Oncology Portfolio at the 2023 ASCO Annual Meeting
-
BeiGene Announces Goals Focused on Sustainable Growth and Workforce Diversity in New ESG Report
-
BeiGene Announces Positive Phase 3 Tislelizumab Trial in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
-
BeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Assoc
-
SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Assoc
-
MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association
-
MapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association
-
BeiGene Expands Presence in Latin America With Opening of Brazil Office
-
BeiGene Appoints Julius Pryor III as First Global Head of Diversity and Health Equity
-
BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey
-
BeiGene Reports Fourth Quarter and Full Year 2022 Financial Results
-
BeiGene (BGNE) Receives 10th Approval for PD-1 Inhibitor Tislelizumab in China
-
BeiGene to Present at Cowen’s 43rd Annual Healthcare Conference
-
BeiGene Receives 10th Approval for PD-1 Inhibitor Tislelizumab in China
-
New Talk About It Resources Aim to Accelerate Integration of Mental Health into Quality Cancer Care
-
BeiGene to Present at Upcoming Investor Conferences
-
BRUKINSA® Approved in the U.S. for Chronic Lymphocytic Leukemia
-
BRUKINSA® (zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) in Great Britain by MHRA
-
BeiGene (BGNE) Announces Expansion of Coverage on China’s National Reimbursement Drug List
-
BeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug List
